Bruce & Co. Inc. Lowers Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)

Bruce & Co. Inc. lowered its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 23.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 323,000 shares of the company’s stock after selling 100,000 shares during the quarter. Kodiak Sciences makes up 1.0% of Bruce & Co. Inc.’s portfolio, making the stock its 22nd biggest holding. Bruce & Co. Inc. owned approximately 0.61% of Kodiak Sciences worth $3,214,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its holdings in Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock valued at $32,000 after acquiring an additional 2,988 shares during the last quarter. US Bancorp DE purchased a new position in shares of Kodiak Sciences during the fourth quarter valued at about $40,000. JPMorgan Chase & Co. increased its holdings in shares of Kodiak Sciences by 220.9% in the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after purchasing an additional 30,735 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Kodiak Sciences by 61.4% in the fourth quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock worth $206,000 after buying an additional 7,871 shares in the last quarter. Finally, Barclays PLC boosted its stake in Kodiak Sciences by 65.5% during the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock valued at $208,000 after buying an additional 31,527 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, December 9th.

Kodiak Sciences Trading Down 4.2 %

Shares of NASDAQ:KOD opened at $3.21 on Friday. The company has a 50-day moving average price of $5.42 and a 200 day moving average price of $5.37. Kodiak Sciences Inc. has a 12 month low of $2.19 and a 12 month high of $11.60. The company has a market cap of $168.92 million, a price-to-earnings ratio of -0.88 and a beta of 2.26.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.